Joseph V. Gulfo

Anthra Pharmaceuticals, Inc. is an American company.

NuGenerex Immuno-Oncology, Inc. is an oncology company focuses on the modulation of the immune system to treat cancer. It develops immunotherapeutic products and vaccines based on proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) class II associated invariant chain that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The company was founded on October 8, 1993 and is headquartered in Miramar, FL.

ProCertus BioPharm, Inc. operates as an oncology-based pharmaceutical company. Its product includes DermX, ProDermaCel, and OralX, proprietary pharmaceuticals which are designed to reduce or eliminate the side effects associated with cancer therapy. ProDermaCel will protect cancer patients from chemotherapy- and radiotherapy-induced alopecia (hair loss), DermX will prevent radiotherapy-induced dermatitis (skin burn), and OralX will protect against chemotherapy- and radiotherapy-induced oral mucositis. The company was founded by William E. Fahl and in 1997 and is headquartered in Madison, WI.

Atropos Technologies LLC provides life sciences research and medical device technologies. Its services include consulting, fund raising, business planning, and development. The firm offers cell printers, micro plate cell incubators, microarray hybridization systems, oligo synthesizers, microarrayers, MIAS-2, and eaZYX imaging products. The company is based in Canton, MA.

Medicus Sciences Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses for its initial business. The company was founded on November 26, 2020 and is headquartered in New York, NY.